Skip to content
AnalystLens

Incyte 8-K Report, Financial Results (Oct 28, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 28, 2025
Period End
October 28, 2025
Security
INCY
In the record · 2016–202610-K1510-Q348-K107

INCY filed 15 annual reports (10-K), 34 quarterly reports (10-Q) and 107 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Oct ’17Oct ’17
  2. Material agreement8-K · Jan ’20Jan ’20
  3. Leadership change8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Jan ’25Jan ’25

01—Abstract

Summary

Summary of the 8-K filed October 28, 2025. Cited figures are marked; the original filing is the authoritative source.

Incyte Corporation reported third-quarter 2025 financial results for the period ended September 30, 2025, with total GAAP revenues of $1.37 billiona, up 20% from the third quarter of 2024.

Total net product revenues were $1.15 billionb, an increase of 19%, driven primarily by patient demand for Jakafi across all indications and strong uptake of the initial launch of Niktimvo. Jakafi net product revenue was $791 million (up 7%), Opzelura net product revenue was $188 million (up 35%), and Niktimvo net revenue was $46 million. GAAP operating income was $443.5 million versus $146.1 million a year earlier, and GAAP net income was $424.2 million, or $2.11 per diluted share, compared with $0.54 per diluted share in the prior-year quarter.

Cash, cash equivalents and marketable securities totaled $2.9 billionc at September 30, 2025. Incyte raised its full-year 2025 net product revenue guidance to $4.23 to $4.32 billion, with Jakafi guidance raised to $3.050 to $3.075 billion and other hematology and oncology products raised to $550 to $575 million. Opzelura guidance of $630 to $670 million was maintained, and GAAP and non-GAAP cost of product revenues, R&D and SG&A expense guidance was reiterated.

The company also said it is pausing development of the INCA034460 (anti-CD122) and INCB57643 (BET inhibitor) programs and povorcitinib in chronic spontaneous urticaria as part of ongoing pipeline prioritization. The quarter also included regulatory and pipeline updates: FDA approval of the Opzelura sNDA for pediatric atopic dermatitis in September, EU and U.S. regulatory submissions for povorcitinib in hidradenitis suppurativa anticipated by year-end 2025 and early 2026, and plans to start a registrational program for INCA33890 in microsatellite stable colorectal cancer in 2026. Incyte also announced a strategic partnership with Enable Injections for the enFuse on-body delivery system to be used with INCA033989.

02—Key points

Key Highlights

  1. Total GAAP revenues of $1.37 billion in Q3 2025, up 20% year over year; total net product revenues of $1.15 billion, up 19%.
  2. Jakafi net product revenue of $791 million (up 7%) and Opzelura net product revenue of $188 million (up 35%); Niktimvo net revenue of $46 million following its launch.
  3. GAAP operating income of $443.5 million vs. $146.1 million in Q3 2024; GAAP diluted EPS of $2.11 vs. $0.54; non-GAAP diluted EPS of $2.26 vs. $1.07.
  4. Full-year 2025 net product revenue guidance raised to $4.23 to $4.32 billion, with Jakafi guidance raised to $3.050 to $3.075 billion and other hematology and oncology products raised to $550 to $575 million.
  5. Opzelura 2025 guidance of $630 to $670 million maintained; GAAP and non-GAAP expense guidance reiterated.
  6. Cash, cash equivalents and marketable securities of $2.9 billion at September 30, 2025, versus $2.2 billion at December 31, 2024.
  7. Pipeline prioritization: development paused for INCA034460, INCB57643 and povorcitinib in chronic spontaneous urticaria; povorcitinib HS submissions expected by year-end 2025 (EU) and early 2026 (U.S.).

03—Questions

Frequently Asked Questions

  1. What drove the revenue growth in the third quarter of 2025?

    Total net product revenues increased 19% to $1.15 billion, primarily due to patient demand for Jakafi across all indications and strong uptake of the initial launch of Niktimvo. Opzelura net product revenue rose 35% to $188 million on increased patient demand and refills in atopic dermatitis and vitiligo.

  2. Did Incyte change its 2025 financial guidance?

    Yes, for net product revenue. Guidance was raised to $4.23 to $4.32 billion, reflecting higher Jakafi demand and other hematology and oncology products, with Jakafi raised to $3.050 to $3.075 billion. Opzelura guidance of $630 to $670 million was maintained, and cost and operating expense guidance was reiterated.

  3. Why did R&D expenses decline in the quarter?

    GAAP R&D expenses fell 12% to $506.6 million, primarily due to a $100 million milestone payment made to MacroGenics in the third quarter of 2024. Excluding upfront and milestone payments and Escient severance payments, R&D expenses increased 7%, driven by continued investment in late-stage development assets.

  4. What pipeline changes did Incyte announce?

    Incyte paused further development of the INCA034460 (anti-CD122) and INCB57643 (BET inhibitor) programs, as well as povorcitinib in chronic spontaneous urticaria, based on ongoing pipeline prioritization. The company also plans to initiate a registrational program for INCA33890 in microsatellite stable colorectal cancer in 2026.

  5. What key regulatory and data milestones are expected next?

    The company expects ruxolitinib XR bioequivalence data to be submitted to the FDA in the fourth quarter of 2025, and regulatory submissions for povorcitinib in moderate to severe hidradenitis suppurativa by year-end 2025 in the EU and early 2026 in the U.S. Phase 1 INCA033989 myelofibrosis results are expected in the second half of 2025, and tafasitamab first-line DLBCL Phase 3 data are anticipated around year-end 2025.

04—Continue

← View all 8-K filings